Trump Drug Pricing Flaw & Gilead Deal: What to Know
A structural gap in Trump's most-favored nation drug pricing framework raises doubts, while Gilead Sciences makes a major autoimmune therapeutics acquisition.
By Robert Kim
CMS
2 articles tagged "CMS"
CMS Chief Tempers TrumpRx Expectations in 2026
CMS administrator Chris Klomp clarified TrumpRx targets the uninsured, not most Americans, countering President Trump's broader claims about the drug discount platform.
By Robert Kim